Yang Ping was silent for a mont: "According to your current treatnt progress and effect, you can return to normal work after the treatnt is completed."
"Very good, thank you!" Lillian’s eyes lit up, "Also, I heard that K Therapy is suitable for several types of tumors. I’ve already contacted so old friends in Europe, so of whom are facing similar health crises. If my treatnt is successful, they will be the next batch of patients. But more importantly, they will bring more resources and attention. I think I can make so contributions to your inclusive plan."
That afternoon, Huang Jiacai ca to Lillian’s ward. This eting was at Lillian’s request, as she wanted to communicate so ideas face-to-face with Huang Jiacai.
"Mr. Huang, I’ve studied all the details of the inclusive frawork," Lillian began directly, "It is very cleverly designed, but there is a potential risk of over-reliance on the high paynt from patients in high-inco countries to subsidize low-inco patients. If the market in high-inco countries fluctuates, the entire system could beco fragile."
Huang Jiacai nodded: "We have considered this problem, so we are promoting inclusion in dical insurance in various countries, while establishing a risk buffer fund to increase other sources of funding."
Huang Jiacai has been thinking about this issue and is trying to find solutions.
Lillian pulled up a chart on her tablet, "I had my financial team do a simulation. With the current cost structure and pricing, if the number of patients in high-inco countries drops by 20%, the entire frawork might incur a deficit. Fluctuations in patient numbers are inevitable, as new drugs hit the market, competition arises, and public opinion shifts, all will have an impact."
Looking at those complex financial models, Huang Jiacai was secretly amazed. This elderly lady from the United Kingdom’s analysis on the hospital bed was more in-depth than that of professional financial teams.
"What’s your suggestion?"
"Diversify funding sources and establish a global unified fund. The fund should be operated on stable investnt returns to ensure that the funds can self-appreciate and cope with inflation," said Lillian, "My foundation can contribute 100 million pounds as seed capital to establish the ’Global K Therapy Alliance Fund.’ This alliance fund can conduct professional and prudent investnts like the Nobel Fund, slowly increasing in value like a snowball. We can use the earnings from this fund to build regional treatnt centers, train local doctors, and develop local drug manufacturing capabilities."
Huang Jiacai imdiately realized the value of this idea. It elevated the inclusive frawork from a business model to a global healthcare infrastructure network.
In doing so, Ruixing’s control might be reduced. If K Therapy can eventually be rolled out worldwide in this way, Ruixing can relinquish so of the so-called control responsibilities, focusing only on mastering core technology, while the subsequent developnt can proceed on its own.
"Ruixing still holds the core technology, which is irreplaceable," Lillian said, "But the promotion and implentation can be more distributed. In fact, this actually lessens your burden; you won’t need to establish teams from scratch in each country, just provide and control standards."
Exactly right, just provide and control the standards, and then let it be distributed and automatically proliferate.
In the corridor, Huang Jiacai encountered Yang Ping and briefly relayed Lillian’s idea.
After listening, Yang Ping simply said: "If this can allow more patients to receive treatnt, it’s a good thing, as long as the technical standards are controlled by us."
...
As Lillian’s plan was still brewing, a special private jet arrived at Shanghai Pudong Airport, carrying not patients, but a secret representative of a multinational giant alliance, Mr. Wu Dechang, and his core team.
They settled into a suite at a top hotel in Lujiazui, beginning the first round of activities for their "China Tour."
The first eting was arranged with the general manager of a state-owned pharmaceutical group, held in a private restaurant on the hotel’s top floor, with the dazzling night view of the Huangpu River outside the window.
"President Zhang, pleased to et you," Mr. Wu Dechang greeted fluently in Chinese, "We greatly admire your group’s achievents in the field of generics. In fact, our partners in India and Brazil have also drawn from your company’s experience."
President Zhang, a shrewd-looking man in his fifties, smiled, "Mr. Wu, you’re too kind. However, as far as I know, your alliance mainly represents the interests of multinational original drug companies, and we are a generics company..."
"Tis are changing." Mr. Wu elegantly cut into his steak, "In the past, original and generic drugs were competitors. But now, we have a common challenger." He deliberately used this term.
"Are you referring to Ruixing?"
"Ruixing, Sanbo, and the entire system behind them," Mr. Wu placed down his knife and fork, "They not only make original drugs but also directly enter the market through the inclusive frawork, capturing market share at an unimaginable speed, leaving no room for any of us. The more crucial thing is that they have done an excellent job of protecting their technology; the core production processes are entirely closed off, making reverse engineering from the international patent docunts impossible."
President Zhang’s eyes glistened, "I heard you have already signed a cooperation agreent with Ruixing?"
"Indeed!" Mr. Wu leaned forward, "But that doesn’t an we can’t collaborate. We can find better ways to cooperate. We can offer expertise and channels for the international market, while your company offers production and localization capabilities. Together, we can develop alternative solutions—not identical, but with similar effects."
User Comments
0 comments from readers